Shire to separate ADHD drugs before possible spin-off, cuts 2020 target
LONDON (Reuters) - London-listed pharmaceutical group Shire said on Monday it would create two distinct business units for its rare disease and hyperactivity medicines before deciding later this year whether to spin off the latter into a separately listed group.
from Reuters: Health News http://reut.rs/2CFPXbq
http://bit.ly/2zwRqiM